Psychotropic medication use and bone loss in men: longitudinal study
BJPsych Open · 2026-03 · 12 (2)
DOI: 10.1192/bjo.2026.10985 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJPsych Open, online erschienen am 11.03.2026. Verfasst von D Kavindi Weerasinghe und 6 weiteren Autor:innen. Beteiligte Einrichtung: https://ror.org/02czsnj07Deakin University, School of Medicine, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, Geelon…. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Psychotropic medication use has been shown to be associated with decreased bone mineral density (BMD) and quality, and increased fracture risk. Less is known about psychotropic use and associated bone loss over time.
Aims
To determine the association between psychotropic medication use and bone loss in men.
Method
Data from 940 men (aged ≥20 years) participating in the Geelong Osteoporosis Study were used in this longitudinal study. BMD (g/cm 2 ) at the spine and hip were measured with dual-energy X-ray absorptiometry at baseline, and 5 and 15 years post-baseline. Body mass index (BMI) was calculated, lifestyle factors and medication use was self-reported, and socioeconomic status was determined. Mood and anxiety disorders were identified through a clinical interview. Multivariable linear regression was used to determine the associations.
Results
Over the study period (median 13.2 years), psychotropic use was associated with change in BMD at the spine (unadjusted mean difference −0.063 g/cm 2 , 95% CI −0.096 to −0.031, p < 0.001) and hip (−0.038 g/cm 2 , 95% CI −0.059 to −0.017, p < 0.001). BMI was identified as an effect modifier. Psychotropic use was associated with spine and hip bone loss at the 25th (adjusted mean difference −0.077g/cm 2 (95% CI −0.122 to −0.033); and −0.058 g/cm 2 (95% CI −0.084 to −0.032), respectively) and 50th percentile (adjusted mean difference −0.053 g/cm 2 (95% CI −0.089 to −0.018) and −0.038 g/cm 2 (95% CI −0.059 to −0.017), respectively), but not the 75th percentile of BMI ( p = 0.121 and p = 0.106, respectively).
Conclusions
Psychotropic use was associated with bone loss in non-obese men, highlighting the need for regular monitoring and preventive strategies to protect bone health.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- https://ror.org/02czsnj07Deakin University, School of Medicine, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, Geelong, Australia.
- Barwon Health, University Hospital, Geelong, Australia.
- Department of Medicine-Western Health, The University of Melbourne, Australia.
- Biostatistics Unit, Faculty of Health, Deakin University, Geelong, Australia.
ORCID-Profile: D Kavindi Weerasinghe
Zitieren
APA
Weerasinghe, D. K., Stuart, A. L., Pasco, J. A., Mohebbi, M., Hodge, J. M., Samarasinghe, R. M., & Williams, L. J. (2026). Psychotropic medication use and bone loss in men: longitudinal study. BJPsych Open, 12(2). https://doi.org/10.1192/bjo.2026.10985
Vancouver
Weerasinghe DK, Stuart AL, Pasco JA, Mohebbi M, Hodge JM, Samarasinghe RM, et al. Psychotropic medication use and bone loss in men: longitudinal study. BJPsych Open. 2026;12(2). doi:10.1192/bjo.2026.10985
BibTeX
@article{Weerasinghe2026,
author = {Weerasinghe, D Kavindi and Stuart, Amanda L and Pasco, Julie A and Mohebbi, Mohammadreza and Hodge, Jason M and Samarasinghe, Rasika M and Williams, Lana J},
title = {Psychotropic medication use and bone loss in men: longitudinal study},
journal = {BJPsych Open},
year = {2026},
volume = {12},
number = {2},
doi = {10.1192/bjo.2026.10985}
}
EUVIMED